Comparing Valuation With Peers: Puma Biotechnology, Inc. (PBYI), IMAX Corporation (IMAX)

Puma Biotechnology, Inc. (NASDAQ:PBYI) is expensive when one looks at the company’s price to sales ratio of 12.33 and compares it with other companies in the Biotechnology group. Its industry average valuation of 112.52 is significantly worse than the sector’s 6.24. In the past 10-year record, this ratio went down as low as 10.72 and as high as 800.31. Also, it is up from 0.5 of the total 726 rivals across the globe.

PBYI traded at an unexpectedly low level on 09/17/2018 when the stock experienced a -6.17% loss to a closing price of $44.1. The company saw 1.27 million shares trade hands over the course of the day. Given that its average daily volume over the 30 days has been 943.81 million shares a day, this signifies a pretty significant change over the norm.

Puma Biotechnology, Inc. (PBYI) Analyst Gushes

Analysts are speculating a 271.88% move, based on the high target price ($164) for the shares that is set to reach in the next 12 months. The analysts, on average, are forecasting a $93.33 price target, but the stock is already up 9.02% from its recent lows. However, the stock is trading at -67.79% versus recent highs ($136.9). Analysts believe that we could see stock price minimum in the $69 range (lowest target price), allowing for another 56.46% jump from its current position. Leading up to this report, we have seen a 3.4% rise in the stock price over the last 30 days and a -19.38% decline over the past 3 months. Overall, the share price is down -55.39% so far this year. Additionally, PBYI had a day price range of $43.75 to $46.75.

Puma Biotechnology, Inc. (PBYI) Price Potential

Heading into the stock price potential, Puma Biotechnology, Inc. needs to grow just 84.81% to cross its median price target of $81.5. In order to determine directional movement, the 50-day and 200-day moving averages for Puma Biotechnology, Inc. (NASDAQ:PBYI) are $45.26 and $56.47. Given that liquidity is king in short-term, PBYI is a stock with 39.12 million shares outstanding that normally trades 11.03% of its float. The stock price recently experienced a 5-day loss of -7.84% with 2.43 average true range (ATR). PBYI has a beta of -0.25 and RSI is 42.94.

Investors also need to beware of the IMAX Corporation (NYSE:IMAX) valuations. The stock trades on a P/S of 3.86, which suggests that the shares are attractive compared with peers. The broad Entertainment – Diversified industry has an average P/S ratio of 7.48, which is significantly better than the sector’s 21.47. In the past 13-year record, this ratio went down as low as 1 and as high as 11.07. Also, it is down from 0.75 of the total 395 rivals across the globe.

IMAX Corporation (IMAX)’s Lead Over its Technicals

IMAX Corporation by far traveled 32.28% versus a 1-year low price of $18.98. The share price was last seen -0.2% lower, reaching at $25.1 on Sep. 17, 2018. At recent session, the prices were hovering between $24.7 and $25.425. This company shares are 13.86% off its target price of $28.58 and the current market capitalization stands at $1.57B. The recent change has given its price a 7.84% lead over SMA 50 and -5.99% deficit over its 52-week high. The stock witnessed 10.33% gains, 12.3% gains and 24.57% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found IMAX’s volatility during a week at 2.45% and during a month it has been found around 2.64%.

IMAX Corporation (NYSE:IMAX) Intraday Metrics

IMAX Corporation (IMAX) exchanged hands at an unexpectedly low level of 1.24 million shares over the course of the day. Noting its average daily volume at 619.83 million shares each day over the month, this signifies a pretty significant change over the norm.

IMAX Corporation Target Levels

The market experts are predicting a 35.46% rally, based on the high target price ($34) for IMAX Corporation shares that is likely to be hit in the 52 weeks. Analysts anticipate that traders could see stock price minimum in the $24 range (lowest target price). If faced, it would be a -4.38% drop from its current position. Overall, the share price is up 8.42% year to date.